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Abstract: (1) Background: Lateral or total parotidectomy are the standard surgical treatments
for malignant parotid tumors. However, some authors have proposed a more limited procedure.
(2) Methods: We performed a review of the literature on this topic. Studies were included that met
the following criteria: malignant parotid tumors, information about the extent of surgical resection,
treated with less than a complete lateral lobectomy, and information on local control and/or survival.
Nine articles fulfilled the inclusion criteria. (3) Results: Eight of the nine series reported favorable
results for the more limited approaches. Most used them for small, mobile, low-grade cancers in
the lateral parotid lobe. Most authors have used a limited partial lateral lobectomy for a presumed
benign lesion. The remaining study analyzed pediatric patients treated with enucleation with poor
local control. (4) Conclusions: There is weak evidence for recommending less extensive procedures
than a lateral parotid lobectomy. In the unique case of a partial lateral parotidectomy performed for
a tumor initially thought to be benign but pathologically proved to be malignant, close follow-up
can be recommended for low grade T1 that has been excised with free margins and does not have
adverse prognostic factors.
Keywords: primary malignant parotid tumors; parotid malignancy; parotid tumors; partial parotid
surgery; parotid surgery
1. Introduction
Surgery is considered the primary treatment modality for most malignant parotid tumors.
The extent of the surgery depends mainly on the local extent of the disease [1–10]. In advanced tumors
(T3 and T4), there is consensus that a total parotidectomy is the standard local treatment. In contrast,
for early tumors (T1, N0), the extent of resection is still controversial. The standard approach has
been total parotidectomy or lateral parotid lobectomy. One debated issue is whether to extirpate the
deep lobe of the gland to remove the intraparotid deep lobe nodes [1–10]. This is done when there is
evidence of superficial parotid or neck node metastasis from a parotid gland cancer, or if the tumor is of
high-grade histology. Controversy regarding the extent of the gland to be removed also occurs as some
recommend [11] a more limited resection than complete lateral lobectomy. Limited parotid surgery is
becoming more frequent in the management of benign tumors, and as a result, more malignant tumors
are incidentally found after partial surgery. When limited parotid surgery is done for a presumably
benign tumor, and final histology reveals malignancy, subsequent treatment is often dictated by the final
pathologic findings. For most cancers, the standard advice is to complete a total parotidectomy [1–8].
Recently, some advocate “watchful waiting”, for small, low-grade, and free-margin resections [12].
The objective of this article is to review the literature regarding the use of partial parotid surgery for
the treatment of malignant parotid tumors and try to define the proper indications for such procedures.
2. Materials and Methods
To analyze the role of limited resections for malignant primary parotid tumors, we conducted
a systematic review of the current literature. A PubMed internet search was performed for English
language publications between the years 1990 and 2019, using the following search criteria in the title
or abstract: “parotid gland malignant tumor” or “parotid gland cancer” or “parotid surgery”.
The search results were reviewed for potential eligible studies. When any abstract addressed
procedures less extensive than lateral parotid lobectomy, the full article was searched. References were
cross-checked to ensure inclusion of all relevant publications. Studies were selected if they met the
following inclusion criteria: (1) patients treated for malignant parotid tumors, (2) information about
the extent of surgical resection, (3) patients treated with less than lateral lobectomy, and (4) information
on local control and/or survival.
Our search criteria identified 61 papers for data review and 9 articles fulfilled the inclusion criteria.
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3. Results
The nine articles (Table 1) are presented in the order of publication, but three articles of the same
group are analyzed together.
Table 1. Publications in partial surgery for parotid malignant tumors.
Year Authors Number of Cases.Complementary Treatment
Histolo-Gical
Type
Local Control (LC)
and Survival
1999 Renehan et al. [13] 24 extracapsular dissection (ECD)(13 post-op radiotherapy)
No specific
information
79% LC (5 recurrences).
68% 10 years overall
survival.
1999 Witt [14]
1 PLL (low-grade, <3 cm)
(No information on
complementary treatment)
1 MEPCA 100% LCNo data on survival
2003 McGurk et al. [15]
12 ECD in selected cases (discrete,
mobile, and less than 4 cm
in diameter)
(7 post-op radiotherapy)
1 ACC
1 AdCC
7 MEPCA
3 others (no
specified)
91.7% LC (1 recurrence)
100% The 10-year
cancer-specific survival
2005 Lim et al. [11]
43 “conservative parotidectomy”
(less than superficial)
(10 post-op radiotherapy)
Low-grade:
11 ACC
9 MEPCA
6 BCC
1 AdCC
High-grade:
5 MEPCA
4 AdCC
3 CEPA
2 ADC
2 SCC
90.5% LC (4
recurrences)
88% 5 years overall
survival
2016 Cockerill et al. [16]
11 Enucleation
(No information on
complementary treatment)
No specific
information 36% LC (7 recurrences)
2017 Stodulski et al. [17]
2 PLL (II) low-intermediate grade,
(one T1 and one T2) with close
margins
(No post-op radiotherapy)
1 AdCC
1MEPCA
100% LC
100% cancer-specific
survival
2019 Mantsopoulos et al.[12,18,19]
14 ECD low grade (13 T1 and one
T2). Free margins
(No post-op radiotherapy)
4 ACC
1 BCC
2 CEPA
7 MEPCA
100% LC
100% cancer-specific
survival
TOTAL CASES PLL 46 cases(10 post-op radiotherapy) 91% (4 recurrences)
TOTAL CASES ECD 50 cases (20 post-op radiotherapy) 88% LC (6 recurrences)
Enucleation 11 cases(no information on radio) 36% LC (7 recurrences)
ACC, acinic cell carcinoma; ADC, adenocarcinoma; AdCC, adenoid cystic carcinoma; CEPA, carcinoma ex
pleomorphic adenoma; BCC, basal cell adenocarcinoma; ED, extracapsular dissection; MEPCA, mucoepidermoid
carcinoma; PLL, partial superficial parotidectomy; SCC, squamous cell carcinoma.
Renehan et al. [13] reported on 24 patients with a primary malignant parotid tumor treated by
extracapsular dissection (ECD). Those tumors were classified as apparently benign, but definitive
histology revealed malignancy. Of those 24 cases, 13 (54%) received postoperative radiotherapy.
The rate of local control was 79% (5 recurrences), and the 10-year overall survival was 68%. The authors
analyzed the subgroup (12 patients) with mobile tumors < 4 cm treated with extracapsular dissection.
Of these, 50% received post-operative radiotherapy. In this subgroup, the local control rate was 80%
and the 10-year survival was 100%. The authors stated than a conservative surgical approach for small,
apparently “benign” parotid cancers did not compromise local control and survival rates.
Witt [14] published his experience with partial lateral lobe parotidectomy (PLL). Most of these PLL
were done for benign tumors, but one patient had a low-grade mucoepidermoid carcinoma. It was a
small (<3 cm) mobile tumor in the lateral lobe (<3 cm). The author reported good facial nerve function
and no evidence of local recurrence.
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McGurk et al. [15] published their experience with 821 patients, where 5% of benign tumors
were subsequently shown to be malignant. The tumors were classified based on clinical criteria
by the authors as simple (discrete, mobile, and less than 4 cm in diameter), and were treated with
ECD. Definitive pathology revealed 12 patients with a malignant tumor treated by ECD, and of those,
five did not have close or positive margins. The seven patients with a close or positive margin or with
a high-grade tumor received postoperative radiotherapy. The outcome of those patients was good,
with local recurrence in only one patient and a 10-year disease-specific survival of 100%. The authors
concluded that ECD is a viable alternative to lateral lobectomy for selected tumors.
Lim et al. [11] published the results of “conservative parotidectomy”, defined as any procedure less
extensive than a lateral lobectomy in which less than the full facial nerve was exposed. They presented
a series of 43 patients with a parotid cancer limited to the lateral lobe. Sixteen (37%) were high-grade
and 27 (63%) were low-grade cancers. Surgical treatment was followed by radiotherapy for 10 patients.
Radiotherapy was indicated when there was the presence of multiple metastases, extracapsular spread,
metastases found on histopathological evaluation, or if histopathological evaluation of the resected
primary tumor demonstrated a positive margin. Local recurrence developed in four cases. The overall
survival rate and the disease-free rate at five years were 88% and 79%. The authors concluded
that conservative parotidectomy with appropriate postoperative radiotherapy may be an acceptable
procedure for the treatment of low-grade parotid cancers confined to the lateral lobe, when the facial
nerve is sufficiently distant from the tumor.
Cockerill et al. [16] reported a large pediatric series of malignant salivary gland tumors, with 49
malignancies originating in the parotid gland. Most were low-grade tumors. The most frequent surgical
approach was total parotidectomy (65%), but a number were treated with enucleation (22%) and the
remainder with lateral lobectomy (10%). The extent of the surgery correlated with loco-regional control,
particularly within the enucleation group, as 64% of these patients had a recurrence. The recurrence
rate after lateral and total parotidectomy was (40%) and (16%). The only statistically significant
difference in tumor control was between enucleation and total parotidectomy. Therefore, the authors
recommend total parotidectomy for tumors with deep-lobe location, high grade, positive intraparotid
lymph nodes or positive cervical lymph nodes. The enucleation of parotid tumors was strongly
discouraged by these authors.
Stodulski et al. [17] analyzed a group of 32 patients, with malignant tumors treated mainly
with surgery with negative (>1 mm) but close (<5 mm) surgical margins, and who did not receive
post-operative radiation. Only two cases were treated with PLL, one T1 and one T2. Neither of those two
cases had recurrence. According to the authors, the watch and wait strategy with intensive follow-up
seemed justified in cases of close margins after the excision of small low-grade parotid tumors.
The same group (Mantsopoulos et al.) published three papers on this subject [12,18,19]. The most
recent [19] was an extension of the two prior papers, with the addition of several new cases.
They reported on 14 patients with a low-grade malignancy treated by ECD and no further surgery
or radiotherapy. All cases were stages pT1-2 pN0. With a mean follow-up of 3.1 years, all patients
remained tumor-free. If the tumor was adequately resected by the primary surgery (R0), the authors
felt that ECD was oncologically sufficient for carefully selected cases. These included completely
removed T1 to T2 low-grade carcinomas (acinic cell carcinoma polymorphous low-grade carcinoma,
low-grade mucoepidermoid carcinoma) and compliant patients for regular follow-up. In their opinion,
ECD alone for these carefully selected tumors did not seem to be associated with a negative oncologic
and functional outcome.
In conclusion, the published data comprises 107 cases, i.e., 46PLL, 50 ECDs and 11 enucleations.
Only Lim et al. [11] performed PLL for suspected malignant tumors. The other surgeons performed
limited surgery for suspected benign tumors. The global local control was 91% for PLL, 88% for ECD
and 36% for enucleation.
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4. Discussion
The object of this review was to analyze the role of limited surgery in the treatment of primary
malignant parotid tumors. Eight of the nine studies [11–15,17–19] supported a limited approach in
carefully selected cases. All were retrospective studies, with a small patient series, and most used
limited resections for small, mobile, clinically benign, but pathologic low-grade cancers of the superficial
lobe. Most authors used these limited surgeries (PLL or ECD) in the setting of a suspected benign
lesion and almost 30% of those patients were treated with post-operative radiotherapy. The advantage
of the “less-than-superficial parotidectomy” approach is that the risk of facial nerve paralysis may
be reduced, hopefully without compromising oncologic results. Three studies used PLL (Lim et al.
defined it as conservative parotidectomy) and the remaining four used ECD for selected cases of
presumed benign tumors.
Primary parotid gland cancers comprise a heterogeneous group of histologic entities with
varying tumor biology and metastatic behavior, ranging from slow growing, less aggressive, to highly
aggressive [20]. This heterogeneity can account for the controversy around the extent of the surgery.
The less aggressive low-grade tumors are the most controversial group. McGurk et al. (15) used the
term simple, or later, “clinical low grade” [21], to refer to the less aggressive tumors. They consider the
clinical grade as the most important factor in tumor classification.
The study showing a negative result for limited surgery was in a pediatric subgroup treated
with enucleation [16]. This enucleation group had a higher rate of local recurrence, and the authors
strongly discouraged this approach. Enucleation is not an acceptable option for even benign tumors.
Enucleation and extracapsular dissection and different surgical techniques can often be very hard to
distinguish by reviewing published papers.
Only one study addressed the management of a suspected malignant tumor [11], with acceptable
local control (90.5%) and post-operative radiotherapy used in 22% of the cases. When a presumably
benign tumor is treated with PLL or ECD and then is found to be a low-grade malignancy,
published data [12–14,17–19] suggest that in highly selected cases, limited resections can be effective.
The typical management is to complete the surgery one would have done if the actual pathology and
tumor extent and behavior were known prior to the first operation. This will best reduce the risk of
loco-regional recurrence [22–30]. However, the studies analyzed here suggest that, for select low-grade,
R0, clinically N0, with no risk factors (Table 2), an observation approach may be a valid option.
Table 2. Proposed indications for malignant parotid tumours, considering two situations: suspected
malign tumour or presumably benign. This is a general guideline; each case needs an individual
decision with open discussion with the patient.
Table Stage Extension of Parotidectomy
Suspected malign
tumour
Stage I-II
(T1-2N0M0)
Low grade (and
superficial)
Lateral parotidectomy
(Less than lateral parotidectomy in very
selected cases can be considered,
but more prospective data are needed
to generalise this indication)
High grade or
intermediate grade or
any grade in deep lobe
Total parotidectomy
Stage III–IV Total parotidectomy
Presumably, benign
tumour but definitive
histology reveals
malignancy *
Stage I-II (pT1-2 N0M0)
Free margins, superficial,
low grade Close follow-up
Margins affected, more
than low grade Complete a total parotidectomy
Stage III–IV Complete a total parotidectomy **
* This situation must be minimized using complete preoperative studies. ** Individualize in relation of the prognostic
factors and the need of radiotherapy +− chemotherapy).
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There is great value in assuring negative margins, as loco-regional control remains an important
factor in long-term oncologic success. Achieving a negative surgical margin is one of the few prognostic
factors in salivary gland malignancies that is controlled by the surgeon [24]. Unfortunately, the margin
status is not always reported in clinic-pathological studies of salivary gland tumors.
Mantsopoulos et al. [18,19] reported on 25 patients where revision parotidectomy was performed
after ECD. Further tumor cells were detected in the histology specimens in only three cases. One of
these three cases had a low-grade tumor. Controversy as to the extent of the resection occurs mainly for
low grade tumors. The amount of gland resected depends on the tumor type, location, and involvement
of intraparotid and regional nodes.
As surgery for benign parotid tumors has evolved to include more conservative resections [31–34],
there will be more cases of presumably benign tumors that are later found to be malignant.
Furthermore, the incidence of malignant parotid tumors seems to have increased in recent
years [35], especially T1 and T2 tumors. Table 2 gives a general guideline for treatment of these
patients, but each case needs individual decision-making, including an open discussion with the
patient. Low-grade tumors generally include low grade mucoepidermoid carcinoma, acinic cell
adenocarcinoma, epithelial-myoepithelial carcinoma, polymorphous low-grade adenocarcinoma,
hyalinizing clear cell carcinoma, basal cell adenocarcinoma, sebaceous adenocarcinoma,
sebaceous lymphadenocarcinoma, mucinous adenocarcinoma, papillary cystoadenocarcinoma,
myoepithelial carcinoma, oncocytic carcinoma, and hyalinizing clear cell carcinoma. We usually
recommend a lateral lobectomy as the standard procedure for these early low-grade malignant parotid
tumors, if there is no involvement of the parotid and regional nodes and the tumor can be widely
excised. We recognize that a partial parotidectomy can also be done for very select low-grade small
peripheral favorably behaving tumors. It is important to assure adequate follow-up for these patients.
More cases are needed to confidently recommend this paradigm shift in management.
Finally, one should try to reduce the occurrence of unexpected malignancy found on permanent
pathology. Published data show an incidence of this between 3% and 5%. McGurk et al. [15]
demonstrated that 32 of 662 clinically “benign” cases (4.8%) were subsequently found to have
malignant histology, with two-thirds of them being low-grade carcinomas. Mantsopoulos et al. [18,19]
found this situation in 30 out of 878 (3.4%) cases, with low-grade malignancies in 22 out of 30
(73.3%) cases.
The ideal preoperative work-up for a presumably benign parotid tumor may reduce this rate by
careful attention to history and tumor behaviour, performing an FNA, and having readily available
frozen section pathology for intraoperative decision making. Many authors [3,5–7,9,36,37] are in favor
of a complete preoperative study with fine needle aspiration cytology (FNAC). Some authors [38,39]
support the role of core needle biopsy (CNB) in the preoperative diagnosis of parotid neoplasms.
An accurate preoperative work-up and intraoperative frozen section pathology should result
in optimal surgical planning and counselling of the patient. This would avoid the emotional and
psychological distress caused for patients having to consider a second surgery.
5. Conclusions
Based on the current literature, there is little evidence to recommend less than a comprehensive
lateral parotid lobectomy for known low-grade primary malignant parotid tumors.
If a partial lobectomy has been performed for a presumably benign tumor that proves to be
a low-grade malignancy; then, if the tumor is stage T1, with free margins, close follow-up may be
recommended. Considering the potential additional morbidity of future recurrence, it is important to
improve preoperative diagnosis and intraoperative diagnosis for optimal surgical management.
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